Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | PRSS1 | P07477 | 9/20 | 0.60 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.58 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7384522 | 0.98 | LMNA (0.67) | LMNAPRSS1PRSS2PRSS3TDP1 | |
| Hydrochloric Acid SCHEMBL6369255 | 0.84 | LMNA (0.72) | LMNATDP1MAPTMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL13269367 | 0.83 | PRSS1 (0.60) | LMNAPRSS1PRSS2PRSS3MAPT | |
| SCHEMBL12857754 | 0.83 | LMNA (0.65) | LMNATDP1MAPTMEN1KMT2A | |
| SCHEMBL1470130 | 0.82 | LMNA (0.74) | LMNATDP1MAPTMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL11294839 | 0.82 | LMNA (0.59) | LMNAPRSS1TDP1MAPTMEN1 | |
| Hydrochloric Acid SCHEMBL9202510 | 0.81 | TSHR (0.63) | PRSS1PRSS2PRSS3MAPTKMT2A | |
| SCHEMBL4873598 | 0.81 | PRSS1 (0.59) | LMNAPRSS1PRSS2PRSS3MAPT | |
| SCHEMBL1063063 | 0.81 | LMNA (0.67) | LMNATDP1MAPTMEN1KMT2A | |
| SCHEMBL31174170 | 0.80 | LMNA (0.77) | LMNATDP1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109553608-A | The purposes of a kind of five yuan of 6-membered heterocyclic compounds and preparation method thereof and treatment tumour | 北京大学 | 2019-04-02 | — | — | CN | disclosed |
| CN-109554469-A | The tumour cell and its molecular marker of T cell acute lymphatic leukemia | 北京大学 | 2019-04-02 | — | — | CN | disclosed |
| CN-109554468-A | PU.1 inhibitor and its application | 北京大学 | 2019-04-02 | — | — | CN | disclosed |
| US-9181280-B2 | Factor VIIa inhibitor | PHARMACYCLICS LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140221667-A1 | FACTOR VIIA INHIBITOR | PHARMACYCLICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8729117-B2 | Factor VIIa inhibitor | PHARMACYCLICS, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20140080879-A1 | FACTOR VIIA INHIBITOR | PHARMACYCLICS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8415328-B2 | Factor VIIa inhibitor | PHARMACYCLICS, INC (US) | 2013-04-09 | — | — | US | disclosed |
| US-20110207939-A1 | FACTOR VIIA INHIBITOR | PHARMACYCLICS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| US-20080275250-A1 | Factor Viia Inhibitor | PHARMACYCLICS, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080242644-A1 | Factor Viia Inhibitor | PHARMACYCLICS, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| EP-1761504-A2 | FACTOR VIIA INHIBITOR | PHARMACYCLICS, INC. (US) | 2007-03-14 | — | — | EP | disclosed |
| EP-1751114-A2 | FACTOR VIIA INHIBITOR | PHARMACYCLICS, INC. (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005121102-A2 | FACTOR VIIA INHIBITOR | PHARMACYCLICS, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005118554-A2 | FACTOR VIIA INHIBITOR | PHARMACYCLICS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| WO-1999026932-A1 | BY AMIDINO GROUP SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTICOAGULANTS | AXYS PHARMACEUTICALS, INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| EP-0009163-B1 | Substituted bisbenzimidazole derivatives, their preparation and antiprotozoic and antiviral agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-06-30 | — | — | EP | disclosed |
| EP-0009163-A2 | Substituted bisbenzimidazole derivatives, their preparation and antiprotozoic and antiviral agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242644-A1 | Factor Viia Inhibitor | F7, F9, F5 | PARP1 2090/4885LMNA 534/4885PRSS1 231/4885 |
| US-20110207939-A1 | FACTOR VIIA INHIBITOR | F7, F9, F5 | PARP1 2090/4885LMNA 534/4885PRSS1 231/4885 |
| US-20140080879-A1 | FACTOR VIIA INHIBITOR | F7, F9, F5 | PARP1 2090/4885LMNA 534/4885PRSS1 231/4885 |
| US-20140221667-A1 | FACTOR VIIA INHIBITOR | F7, F9, F5 | PARP1 2090/4885LMNA 534/4885PRSS1 231/4885 |
| US-20080275250-A1 | Factor Viia Inhibitor | F7, F9, F5 | PARP1 2086/4885LMNA 552/4885PRSS1 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.